Skip to content

Preliminary study of the effect of tokishakuyakusan on ocular blood flow in the patients with normal tension glaucoma

Preliminary study of the effect of tokishakuyakusan on ocular blood flow in the patients with normal tension glaucoma - The effect of tokishakuyakusan on ocular blood flow in the patients with normal tension glaucoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000016865
Enrollment
30
Registered
2015-03-21
Start date
2015-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

normal tension glaucoma

Interventions

Traditional Japanese Kampo medicine tokishakuyakusan (TJ-23), 7.5g/day, orally, for 6 months

Sponsors

Tohoku university
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. systolic blood pressure < 130 mmHg and systolic blood pressure < 85 mmHg 2. intra ocular pressure <= 21 mmHg 3. with no significant abnormality in an examination for slit lamp microscopy and angle 4. with glaucoma-related optic disc shape in funduscopy 5. with glaucoma-related field change by at least two times of reliable visual field tests 6. written informed consent can be obtained from the participant

Exclusion criteria

Exclusion criteria: 1. When there is hypotension, circulatory disease, endocrine disease, a cause including excessive anemia are identified, and the cause is judged if treatment is necessary. 2. pregnant 3. history of allergy to Kampo medicine 4. history of unpleasantness, gastrointestinal disorder by the Kampo medicine

Design outcomes

Primary

MeasureTime frame
ocular blood flow

Countries

Japan

Contacts

Public ContactShin Takayama

Tohoku University Graduate School of Medicine Comprehensive Education Center for Community Medicine

takayama@med.tohoku.ac.jp022-717-8010

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026